Editorial Board About Us

Erectile dysfunction

All articles from this key word are listed below.

Volume 7, Supplement 2 Review Articles

Advances in the Management of Post-Radical Prostatectomy Erectile Dysfunction: Treatment Strategies When PDE-5 Inhibitors Don't Work

Radical prostatectomy Erectile dysfunction Intracavernous injectiontherapy MUSE Vacuum erection devices Combination pharmacotherapy

Volume 7, Supplement 2 Review Articles

Neuroregenerative Strategies After Radical Prostatectomy

Robert C Dean Tom F Lue

Radical prostatectomy Erectile dysfunction Gene therapy Impotence

Volume 7, Supplement 2 Review Articles

Penile Prosthesis Implantation for End-Stage Erectile Dysfunction After Radical Prostatectomy

Drogo K Montague

Radical prostatectomy Erectile dysfunction Penile prostheses

Volume 8, Number 4 Review Articles

Penile Rehabilitation After Radical Prostatectomy: Important Therapy or Wishful Thinking?

Management Update

Joseph E Dall'Era Hari K Koul Randall B Meacham Jesse N Mills

On the basis of data accumulated thus far, it is reasonable to discuss the implementation of a “penile rehabilitation” program with patients undergoing radical prostatectomy. Central to discussions of penile rehabilitation after radical prostatectomy is evidence demonstrating significant fibrotic changes in the corpus cavernosum that occur postoperatively. Several studies have been published evaluating the efficacy of various pro-erectogenic agents. The limited data regarding intracavernous injections and vacuum constriction devices suggest that an increased percentage of treated patients experienced a return of natural erections compared with patients who received no treatment. Longer, prospective, randomized, placebo-controlled studies will be needed to confirm the utility of these treatments. Data from contemporary studies evaluating the chronic use of oral phosphodiesterase type 5 inhibitors suggest a beneficial effect on endothelial cell function among men suffering from erectile dysfunction due to a variety of causes. Limited data suggest that this effect might be seen among post-prostatectomy patients, implying a possible role for these agents in enhancing the return of sexual function in such individuals. [Rev Urol. 2006;8(4):209-215]

Radical prostatectomy Erectile dysfunction Penile rehabilitation PDE-5 inhibitors Hypoxia Intracorporeal injection Vacuum constriction device

Volume 8, Number 3 Meeting Reviews

Best of the 2006 AUA Annual Meeting

Meeting Review

Li-Ming Su Tobias Klatte Michael E Aldridge John P Mulhall Shachi Tyagi Danil V Makarov John P Stein Arie S Belldegrun Michael K Brawer Claus G Roehrborn Jacob Rajfer J Curtis Nickel Victor W Nitti Michael B Chancellor Alan W Partin Ellen Shapiro

Highlights from the 2006 Annual Meeting of the American Urological Association May 20–25, 2006 Atlanta, GA

Prostate cancer Infertility Benign prostatic hyperplasia Bladder cancer Kidney cancer Lower urinary tract symptoms Bladder exstrophy Overactive bladder Interstitial cystitis Stress urinary incontinence Peyronie’s disease Spina bifida Neurogenic bladder Erectile dysfunction Chronic pelvic pain syndrome Chronic prostatitis Tumor markers Androgen replacement therapy Ejaculatory dysfunction Anorectal malformations Renal stones Robotic-assisted radical prostatectomy

Volume 8, Number 2 Review Articles

Erectile Function Outcomes in the Current Era of Anatomic Nerve-Sparing Radical Prostatectomy

Therapeutic Challenges

Arthur L Burnett

The contemporary use of anatomic nerve-sparing radical prostatectomy, which entails preserving the autonomic nerve supply to the penis required for penile erection, has led to improved erectile function outcomes compared with what has been seen historically. However, delay of postoperative recovery of erection for as long as 2 years is common, such that dysfunctional erection status lingers as a major postoperative problem. Several possible strategies to improve overall recovery rates and to hasten postoperative recovery of erectile function are currently being advanced. These include pharmacologic rehabilitation therapy and neuromodulatory therapy. Rigorous basic scientific investigation and clinical assessment of these new strategic approaches are critically important to establish their actual therapeutic benefits. [Rev Urol. 2006;8(2):47-53]

Prostate cancer Radical prostatectomy Erectile dysfunction Neuromodulation Penile erection

Volume 9, Number 4 Review Articles

Extending the Rationale of Combination Therapy to Unresponsive Erectile Dysfunction

Treatment Update

Rajeev Kumar Ajay Nehra Diedre Nienow Christopher Reece

Combination therapies aim to overcome the limitations of individual drugs by selecting diverse targets of action to enhance effectiveness synergistically. This article reviews the principles of combination therapy and its applications for benign prostatic hyperplasia and overactive bladder. It then examines pathophysiological, pharmacological, and clinical evidence for currently available drug and device combinations for erectile dysfunction that has not responded to first-line, single-agent therapy. [Rev Urol. 2007;9(4):197-206]

Benign prostatic hyperplasia Overactive bladder Erectile dysfunction Combination therapy Intracavernosal therapy Intraurethral therapy

Volume 9, Number 3 Review Articles

Oral and Non-Oral Combination Therapy for Erectile Dysfunction

Treatment Update

An estimated 30 million men in the United States suffer from varying degrees of erectile dysfunction. Increasing age and comorbidities are likely to increase the number of men who are initially refractory or become refractory to phosphodiesterase (PDE)-5 inhibitors, the most popular oral therapy. Combination therapy, a concept well proved in other areas of medicine, is therefore of increasing importance. Combination oral and non-oral (intracavernosal injection and intraurethral application) therapies have been shown to salvage monotherapy. The early introduction of combination therapy has been shown to expedite both the return of natural function and PDE-5 inhibitor responsiveness in post-prostatectomy patients with no reports of serious adverse events. Larger controlled studies are needed to corroborate those encouraging findings. [Rev Urol. 2007;9(3):99-105]

Erectile dysfunction Phosphodiesterase inhibitors Intracavernosal injection Intraurethral application Alprostadil

Volume 9, Number 2 Review Articles

Phosphodiesterase Type 5 Inhibitors for the Treatment of Male Lower Urinary Tract Symptoms

Treatment Update

Ricardo R Gonzalez Steven A Kaplan

Both lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) and erectile dysfunction have a very high prevalence among aging men, and there is some clinical evidence that they may share a common pathophysiology. Consequently, several preliminary studies of phosphodiesterase type 5 inhibitors—sildenafil and tadalafil—have recently been conducted in men with concomitant erectile dysfunction and lower urinary tract symptoms to determine whether these agents are effective for the treatment of symptomatic BPH. These studies have demonstrated efficacy, both alone and in combination with an -blocker, in treating lower urinary tract symptoms along with sexual dysfunction. However, larger-scale randomized studies are necessary to determine long-term safety, efficacy, and cost effectiveness. [Rev Urol. 2007;9(2):73-77]

Benign prostatic hyperplasia Lower urinary tract symptoms Erectile dysfunction Tadalafil Sildenafil Phosphodiesterase type 5 inhibitors

Volume 10, Number 3 Meeting Reviews

Advances in Sexual Medicine

Meeting Review

John P Mulhall Jacob Rajfer

Highlights from the 2007 Winter Meeting of the Sexual Medicine Society of North America, December 6-9, 2007, Chicago, IL [Rev Urol. 2008;10(3):232-235]

Radical prostatectomy Erectile dysfunction Phosphodiesterase type 5 inhibitors Stem cells Spinal cord injury Penile implant surgery